Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to …
Bristol-Myers Squibb (NYSE: BMY) investors might have been just a bit worried on Wednesday. After all, the U.S. Food and Drug Administration (FDA) had just placed a partial clinical hold on three clinical trials for Opdivo in combination …
The third-quarter earnings season is off to a strong start. The results of the companies that have reported numbers show that earnings and revenue growth pace is accelerating from the first two quarters. In particular, revenue growth has …
Major pharma companies like Eli Lilly LLY, Bristol-Myers Squibb BMY, GlaxoSmithKline plc GSK and Novartis (Read more: Novartis Q3 Earnings & Sales Top on New Drugs Strength) reported third quarter results this week. While it was …
Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to …
Bristol-Myers shares have increased almost 4 percent since the beginning of the year, while the Standard & Poor's 500 index has risen slightly more than 3 percent. The stock has climbed 25 percent in the last 12 months. This story was …
Yahoo!4mon
Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to …